-The Telegraph New Delhi: A government agency has blocked its own pledge to impose price control on more medicines by withdrawing guidelines that it had used in July this year to cap prices of drugs used to treat diabetes and cardiovascular diseases. The National Pharmaceutical Pricing Authority (NPPA) has withdrawn the guidelines issued under Paragraph 19 of the Drug Price Control Order that it had used in July this year to cap...
More »SEARCH RESULT
Total Matching Records found : 72
Government curbs power of regulator to cap HIV, cancer drug prices -Rupali Mukherjee
-The Times of India MUMBAI: In a move that will disappoint many patients, the government has withdrawn certain powers of the drug pricing regulator that allowed it to cap prices of widely prescribed anti-diabetes, cancer, HIV, tuberculosis and cardiac medicines. The National Pharmaceutical Pricing Authority (NPPA) said it is withdrawing "with immediate effect" - a guideline that had allowed it to put price caps on crucial medicines - to comply with a...
More »Major diabetes, cardiac drugs to become up to 35% cheaper -Rupali Mukherjee
-The Times of India MUMBAI: In a move that has surprised and shaken the industry, prices of widely-used expensive anti-diabetic and cardiac medicines will reduce by as much as 35% over the next few weeks, with the drug pricing regulator, National Pharmaceutical Pricing Authority (NPPA), deciding to bring them under price control. In a rare invocation of a lesser-used provision in the Drug Price Control Order (DPCO), NPPA has fixed the prices...
More »New drug pricing creates artificial scarcity-Shyama Rajagopal
-The Hindu Kochi: An artificial scarcity of drugs looms large with the new drug pricing regime, slashing prices for 348 essential drugs, set to prevail from July 29. Many retailers who stock medicines for a week are not picking up medicines and are keeping a minimum inventory. Some retailers said distributors were not making medicines available. It has sent medical retail stores into a tizzy about the fate of already available stocks. J.S....
More »Price control, IP Act & regulatory framework: Revisiting some imp issues about Indian pharma-Ramesh Adige
-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »
